Antimicrobial therapy for bone and joint infections

Current Infectious Disease Reports

Volumn 11, Issue 1, 2009, Pages 7-13

  Aslam, Saima ^a   Darouiche, Rabih O ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NAFCILLIN; OFLOXACIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPECTINOMYCIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL ARTHRITIS; BONE INFECTION; CHRONIC OSTEOMYELITIS; CLINICAL TRIAL; DEBRIDEMENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; INCIDENCE; INFECTIOUS ARTHRITIS; KIDNEY FUNCTION; LIVER FUNCTION; MORBIDITY; MULTIDRUG RESISTANCE; NONHUMAN; OPERATION DURATION; OSTEOMYELITIS; PATIENT COMPLIANCE; PROSTHESIS INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TREATMENT DURATION;

EID: 67649399083     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0002-x     Document Type: Review

References (52)

1. Tice AD, Hoaglund PA, Shoultz DA: Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003, 114:723-728.
2. Ohl CA: Infectious arthritis of native joints. In Principles and Practice of Infectious Diseases, edn 6. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Elsevier; 2005:1311-1322.
3. Shirtliff ME, Mader JT: Acute septic arthritis. Clin Microbiol Rev 2002, 15:527-544.
4. Lew DP, Waldvogel FA: Osteomyelitis. Lancet 2004, 364:369-379.
5. Lew DP, Waldvogel FA: Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 1999, 58(Suppl 2):85-91.
6. Bernard L WF, Lew DP: Treatment of osteomyelitis and septic arthritis. In Quinolone Antimicrobial Agents, edn 3. Edited by Hooper DC, Rubenstein E. Washington, DC: ASM Press; 2003:251-258.
7. Drancourt M, Stein A, Argenson JN, et al.: Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997, 39:235-240.
8. Drancourt M, Stein A, Argenson JN, et al.: Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993, 37:1214-1218.
9. Stein ADM, Raoult D: Bisno AL. Washington, DC: ASM Press; 2000:211-230.
10. Zimmerli W, Widmer AF, Blatter M, et al.: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279:1537-1541.
11. Chuard C, Herrmann M, Vaudaux P, et al.: Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991, 35:2611-2616.
12. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W: Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992, 14:1251-1253.
13. Schwank S, Rajacic Z, Zimmerli W, Blaser J: Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998, 42:895-898.
14. Perry AC, Prpa B, Rouse MS, et al.: Levofloxacin and trovafloxacin inhibition of experimental fracture-healing. Clin Orthop Relat Res 2003, 414:95-100.
15. de Barros JW, Calapodopulos CJ, Oliveira DJ, Miki Júnior P: The treatment of chronic osteomyelitis. Rev Soc Bras Med Trop 1992, 25:235-239.
16. Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME: Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: A meta-analysis of randomized controlled trials. Spine 2008, 33:E297-E304.
17. Birmingham MC, Rayner CR, Meagher AK, et al.: Linezolid for the treatment of multidrug-resistant, grampositive infections: Experience from a compassionate-use program. Clin Infect Dis 2003, 36: 159-168.
18. Shuford JA, Steckelberg JM: Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis 2003, 16:515-519.
19. Rayner CR, Baddour LM, Birmingham MC, et al.: Linezolid in the treatment of osteomyelitis: Results of compassionate use experience. Infection 2004, 32:8-14.
20. Lipsky BA, Itani K, Norden C: Treating foot infections in diabetic patients: A randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillinclavulanate. Clin Infect Dis 2004, 38:17-24.
21. Rao N, Ziran BH, Hall RA, Santa ER: Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004, 427:67-71.
22. Rouse MS, Piper KE, Jacobson M, et al.: Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006, 57:301-305.
23. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R: Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007, 120(10 Suppl 1):S13-S20.
24. Yin LY, Lazzarini L, Li F, et al.: Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002.
25. Lentino JR: Prosthetic Boint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003, 36:1157-1161.
26. Berbari EF, Hanssen AD, Duffy MC, et al.: Risk factors for prosthetic joint infection: Case-control study. Clin Infect Dis 1998, 27:1247-1254.
27. Bozic KJ, Ries MD: The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg Am 2005, 87:1746-1751.
28. Trautner BW, Darouiche RO:PCatheter-associated infections: pathogenesis affects prevention. Arch Intern Med 2004, 164:842-850.
29. Zimmerli W, Trampuz A, Ochsner PE: Prosthetic-joint infections. N Engl J Med 2004, 351:1645-1654.
30. Norden CW, Shaffer M: Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin. J Infect Dis 1983, 147:352-357.
31. Norden CW: Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis 1975, 132:493-499.
32. Norden CW, Fierer J, Bryant RE: Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 1983, 5(Suppl 3):S495-S501.
33. Norden CW, Keleti E: Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob Agents Chemother 1980, 17:591-594.
34. O'Reilly T, Kunz S, Sande E, et al.: Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: Azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother 1992, 36:2693-2697.
35. Dworkin R, Modin G, Kunz S, et al.: Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990, 34:1014-1016.
36. Zimmerli W, Frei R, Widmer AF, Rajacic Z: Microbiological tests to predict treatment outcome in experimental devicerelated infections due to Staphylococcus aureus. J Antimicrob Chemother 1994, 33:959-967.
37. Saleh-Mghir A, Ameur N, Muller-Serieys C, et al.: Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002, 46:1122-1124.
38. Saginur R, Stdenis M, Ferris W, et al.: Multiple combination bactericidal testing of staphylococcal biofilms from implantassociated infections. Antimicrob Agents Chemother 2006, 50:55-61.
39. Pavoni GL, Giannella M, Falcone M, et al.: Conservative medical therapy of prosthetic joint infections: Retrospective analysis of an 8-year experience. Clin Microbiol Infect 2004, 10:831-837.
40. Rao N, Crossett LS, Sinha RK, Le Frock JL: Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res 2003, 414:55-60.
41. Stein A, Bataille JF, Drancourt M, et al.: Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998, 42:3086-3091.
42. Bassetti M, Vitale F, Melica G, et al.: Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005, 55:387-390.
43. Vercillo M, Patzakis MJ, Holtom P, Zalavras CG: Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007, 461:40-43.
44. Razonable RR, Osmon DR, Steckelberg JM: Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004, 79:1137-1144.
45. Rao N, Regalla DM: Uncertain efficacy of daptomycin for prosthetic joint infections: A prospective case series. Clin Orthop Relat Res 2006, 451:34-37.
46. Coakley G, Mathews C, Field M, et al.: BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology (Oxford) 2006, 45:1039-1041.
47. Sattar MA, Barrett SP, Cawley MI: Concentrations of some antibiotics in synovial fluid after oral administration, with special reference to antistaphylococcal activity. Ann Rheum Dis 1983, 42:67-74.
48. Stengel D, Bauwens K, Sehouli J, et al.: Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001, 1:175-188.
49. Odio CM, Ramirez T, Arias G, et al.: Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003, 22:883-888.
50. Sharp JT, Lidsky MD, Duffy J, Duncan MW: Infectious arthritis. Arch Intern Med 1979, 139:1125-1130.
51. Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance 2003 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report - 2003. Atlanta, GA: US Department of Health and Human Services; 2004.
52. Centers for Disease Control and Prevention: Update to CDC's sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007, 56:332-336.